Biogen Inc. / Sangamo Therapeutics, Inc.

Tauopathies, Synucleinopathies & Neuromuscular Disease (Zinc Finger Gene Regulation)

7.7M US cases/yr · $15.0B Global Alzheimer's & Parkinson's drug market 2020 · $2.72B Total deal BD value (incl. $350M upfront + up to $2.37B milestones)

Disease Overview

The Biogen-Sangamo collaboration covers a portfolio of CNS gene regulation programs led by ST-501 for tauopathies (Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy), ST-502 for synucleinopathies (Parkinson's disease, dementia with Lewy bodies, multiple system atrophy), an undisclosed neuromuscular disease target, and up to nine additional neurological targets. Alzheimer's disease affects approximately 6.7 million U.S. adults age 65 and older, with annual incidence of approximately 250,000 new cases; Parkinson's disease affects approximately 1 million U.S. adults with annual incidence of approximately 60,000. The neurodegenerative disease therapeutic class is anchored by symptomatic care plus emerging disease-modifying treatments — Aduhelm/aducanumab (Biogen, FDA-accelerated approval 2021, withdrawn 2024) and Leqembi/lecanemab (Biogen/Eisai, FDA-accelerated 2023, traditional 2023) for Alzheimer's, and dopaminergic therapies (levodopa, carbidopa, MAO-B inhibitors) for Parkinson's. Zinc finger protein (ZFP) gene regulation, Sangamo's proprietary platform, uses engineered ZFP transcription factors to selectively repress mutant gene expression — for tauopathies, ZFP-TF designs target MAPT (tau) gene transcription; for synucleinopathies, ZFP-TF designs target SNCA (alpha-synuclein). The platform is delivered via AAV gene therapy vectors. WAC pricing for branded Alzheimer's disease-modifying therapies is approximately $26,500 per year (Leqembi).

Competitive Landscape

The neurodegenerative disease competitive landscape spans symptomatic and emerging disease-modifying mechanisms. Alzheimer's disease anti-amyloid antibodies include aducanumab/Aduhelm (Biogen/Eisai, withdrawn 2024), lecanemab/Leqembi (Biogen/Eisai, FDA-approved 2023), donanemab/Kisunla (Eli Lilly, FDA-approved 2024), gantenerumab (Roche, discontinued Phase 3 2022). Tau-directed competitors include zagotenemab (Lilly, discontinued), tilavonemab (AbbVie, discontinued), gosuranemab (Biogen, discontinued), and tau ASOs (BIIB080/MK-2214 Biogen/Ionis Phase 1/2). Parkinson's disease alpha-synuclein modifiers include cinpanemab (Biogen, discontinued), prasinezumab (Roche/Prothena, Phase 2b active), and ASOs targeting SNCA (BIIB101 Biogen/Ionis). Sangamo's ZFP-TF platform is differentiated from antibody, ASO, and small molecule approaches by targeting upstream transcriptional regulation of MAPT and SNCA. Competitor gene therapy CNS platforms include Voyager Therapeutics (AAV, multiple deals with Neurocrine, Pfizer), Sangamo's own competitor in CNS gene therapy is delivery innovator Capsida Biotherapeutics. CRISPR/Cas9 in vivo gene editing competitors (Editas Medicine, Beam Therapeutics base editing, Verve Therapeutics) and RNA-targeting therapies (Wave Life Sciences, Stoke Therapeutics CNS ASOs) round out the genetic medicine competitive set. Symptomatic Alzheimer's therapies (donepezil, rivastigmine, galantamine, memantine) and Parkinson's symptomatic therapies (levodopa-carbidopa, rasagiline, safinamide, opicapone) remain the dominant standard of care with annual U.S. revenue still exceeding the early disease-modifying class. The Biogen partnership consolidates Sangamo's CNS pipeline within Biogen's neurology franchise leadership.